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Adoptive cell therapy using expanded autologous TIL is
a promising immunotherapy for metastatic melanoma.
However, we still know relatively little about the types
of T cells in TIL mediating tumor regression, and there
have been no biomarker studies on the actual tumors
used to expand TIL to identify factors predictive of clin-
ical response. The purpose of this study was to identify
immune biomarkers in tumors used to expand TIL and
determine their power to predict an eventual response
to TIL therapy. We performed immunohistochemistry
(IHC) for a number of parameters (e.g., CD8, CD4,
CD3, FoxP3, and PD-1) on formalin-fixed paraffin-
embedded (FFPE) tumor samples from 48 patients that
expanded TIL and were eventually treated as well as
FFPE samples from 39 patients from which TIL did not
successfully expand. We found a correlation between
the percentage of CD8+ cells in the original tumor by
IHC and the CD8 content of the final expanded TIL
product of these patients (p=0.046, r2=0.283, Spearman
correlation coefficient). We also found highly significant
differences in CD8, CD4 and CD3 staining in tumors
between TIL growers and non-growers (p<0.0001).
Although the percentages of total, peri-tumoral or intra-
tumoral CD8, PD-1 and FoxP3 in the original tumor for
TIL expansion could not predict tumor response (CR/
PR vs. SD/PD), increased peri-tumoral and total CD4
staining had an inverse trend towards predicting CR/PR
(p=0.067 and p=0.082, respectively). Interestingly, when
we combined CD8 and FoxP3 staining and developed a
scoring system that considered the location and extent of
staining, we found that patients who had a lower CD8
and FoxP3 score in peri-tumoral and/or intra-tumoral
areas had significantly shorter overall survival in both
univariate (HR= 3.657, p=0.041) and multivariate
(HR=3.514, p=0.048) Cox proportional hazards analysis.
We also performed gene expression analysis on RNA
isolated from the same tumor samples using a new
NanoString nCounter™ technology. This revealed signi-
ficant differences in a number of immune system-related
genes in tumors of TIL growers and non-growers, such
as CD3ε and CD3δ, STAT4, TRAFs, CD27, ICOS,
IL-21R, TNF-a, FoxP3, and CCR8. There were also
differences in gene expression in tumors of responding
and non-responding patients treated with TIL, such as
BATF3 and IRAK1. Our data suggests that IHC analysis
together with gene profiling of archived FFPE tumor
samples is useful to develop predictive biomarker signa-
tures to select patients for TIL therapy and identify those
who will have a survival benefit for stratification in future
clinical trials.
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